Cephalon shareholders approve acquisition by Teva
This article was originally published in Scrip
Executive Summary
Cephalon shareholders have voted in favour of an offer by Teva Pharmaceutical Industries to buy the biotech for $81.50 per share in cash, or approximately $6.8 billion, and thus Teva is one step closer to a final deal.